BackFulcrum Therapeutics Overview
Fulcrum Therapeutics Inc

Fulcrum Therapeutics Target Price

Where could FULC trade next? Consensus target price: $3.6.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.85

Average Target Price

$3.606.5% downside

5 analysts in the last 4 months

High: $4 | Low: $3

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-02H.C. WainwrightAndrew Fein$322.1% downsideOpen
2026-06-02Jefferies$43.9% upsideOpen
2026-06-02Leerink Partners$43.9% upsideOpen
2026-06-02Truist FinancialGregory Renza$43.9% upsideOpen
2026-06-02Piper Sandler$322.1% downsideOpen
2026-02-24Truist FinancialGregory Renza$17341.6% upsideOpen
2025-12-11Truist Financial$18367.5% upsideOpen
2025-12-08Stifel Nicolaus$25549.4% upsideOpen
2025-12-08Cantor FitzgeraldKristen Kluska$24523.4% upsideOpen
2025-12-08RBC Capital$10159.7% upsideOpen
2025-12-08Piper Sandler$23497.4% upsideOpen
2025-12-08H.C. Wainwright$25549.4% upsideOpen
2025-11-24Truist Financial$14263.6% upsideOpen
2025-11-24H.C. WainwrightAndrew Fein$18367.5% upsideOpen
2025-10-30Piper Sandler$16315.6% upsideOpen
2025-10-21Leerink Partners$20419.5% upsideOpen
2025-07-29H.C. Wainwright$12211.7% upsideOpen
2025-05-29Piper SandlerEdward Tenthoff$9133.8% upsideOpen
2025-05-23Leerink PartnersJoseph Schwartz$12211.7% upsideOpen
2024-09-13H.C. WainwrightAndrew Fein$43.9% upsideOpen
2024-09-12RBC CapitalGregory Renza$43.9% upsideOpen
2024-09-12Stifel NicolausDae Gon Ha downgraded Fulcrum Therapeutics$322.1% downsideOpen
2024-09-12Bank of America SecuritiesTazeen Ahmad$248.1% downsideOpen
2024-09-09Bank of America SecuritiesTazeen Ahmad$10159.7% upsideOpen
2024-09-03RBC CapitalGregory Renza$15289.6% upsideOpen
2024-05-20Cantor FitzgeraldKristen Kluska$23497.4% upsideOpen
2024-05-13Goldman SachsCorinne Jenkins$15289.6% upsideOpen
2024-05-13Stifel NicolausDae Gon Ha$22471.4% upsideOpen
2024-03-13RBC CapitalGregory Renza$14263.6% upsideOpen
2022-11-15Goldman Sachs$11185.7% upsideOpen
2022-11-08Piper SandlerEdward Tenthoff$18367.5% upsideOpen

Fulcrum Therapeutics (FULC) FAQ

The latest target price for FULC is $3.6. Investors often review this figure alongside Fulcrum Therapeutics's historical trend and sector peers before judging valuation or financial health.

Fulcrum Therapeutics trades near $3.85 while the consensus target sits at $3.6 (6.5% downside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting FULC's target price ($3.6), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Fulcrum Therapeutics's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.